Enveric Biosciences closed at $1.43 on Oct 30, down 2.05%, 86.2% below its 52-week closing high. Volume of 12.0K shares was 0.22× its 20-day average (below normal).
Split-adjusted performance: -2.1% over one month, -64.2% over six months, -78.7% over one year.
Short interest was 38.7K shares at the Oct 15 settlement, up 150.7% from the prior report (0.9% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 421 companies (100 = best)
Industry medians: 6-month return −24.3%, revenue growth +6.4%, net margin −35.1%, P/E 15.8×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ENVBEnveric Biosciences | $1.43 | −2.05% | −64.2% | — | — | — | $6.4M | |
| FBLGFibroBiologics | $0.9300 | +0.20% | −36.3% | — | — | — | $6.6M | Compare |
| XCURExicure | $1.01 | +8.04% | −68.8% | — | — | — | $6.6M | Compare |
| NAIINatural Alternatives International | $1.07 | −3.60% | −60.7% | +1.9% | −39.2% | — | $6.7M | Compare |
| APREAprea Therapeutics | $0.4846 | −1.82% | −40.8% | −100.0% | — | — | $6.1M | Compare |
| KPRXKiora Pharmaceuticals | $1.56 | −11.36% | −36.1% | — | — | — | $6.9M | Compare |
| ALZNAlzamend Neuro | $1.21 | −0.82% | +8.0% | — | — | — | $5.8M | Compare |
| ACXPAcurx Pharmaceuticals | $1.04 | −2.80% | −51.9% | — | — | — | $5.7M | Compare |
| SKYESkye Bioscience | $1.28 | −2.29% | −80.6% | — | — | — | $5.7M | Compare |
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
